Clear all search history
Law & Crime
Disasters & Accidents
War & Conflict
Hospitality & Recreation
Rituxan articles over last 30 days
articles last 30 days
articles per day
Mentioned in this news
Global Biosimilars (Recombinant Non-Glycosylated ...
... from 2013 to 2018. The drugs that are expected to lose their patent protections are
/MabThera, Remicade, Herceptin, Humira, Avastin, Synagis, Erbitux, and Lucentis. The three...
Read more at Business Wire
Gene, immune therapy help cancer war
... said. And when used against non-Hodgkin's lymphoma along with an existing antibody drug called
, the result is a potent cancer-killing effect. Immune cells called macrophages actually...
Read more at
San Diego Union-Tribune
American Association for Cancer Research
San Diego Convention Center
Roche to Work With Oryzon to Turn on Cancer-Suppr...
... Roche is pushing to stay atop the field of cancer, where it has led with the Herceptin,
and Avastin medicines even as it struggled to win approval for drugs for other types of...
Read more at
The Irish Times
Roche Holding AG
Competitive Intelligence Report on biosimilar and...
... the discovery and development of biosimilar and biosuperior/biobetter molecules.
/MabThera The report includes a compilation of currently active projects in research and...
Read more at News-Medical-Net
Latest from Twitter
Parts of this website powered by Open Calais, a toolkit for rich semantic metadata extraction.
Interceder is a topic search engine aggregating the latest news on any topic into a single window of information. This page has been automatically generated. To contact Interceder
Your privacy is important. Interceder does not collect and keep any personal information about visitors to the site. Interceder may use third-party advertising companies to serve ads. These companies may use information (not including your name, address, email address, or telephone number) about your visits to this and other websites in order to provide advertisements on this website, other websites, and other forms of media about goods and services of interest to you.